Anti-MEF2A (Ab-319) antibody produced in rabbit, affinity isolated antibody

Not available outside of the UK & Ireland.

Biochem/physiol Actions

MEF2A (myocyte enhancer factor 2A) mutation is associated with an autosomal dominant form of CAD (coronary artery disease).

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

General description

MEF2A (myocyte enhancer factor 2A) belongs to the myocyte enhancer family of transcription factors. MEF2 codes for proteins, which helps to attach to a consensus CTA(T/A)4TAG/A sequence as homo- and heterodimers. It is mapped to chromosome 15q26.

Immunogen

Peptide sequence around aa. 317-321 (V-T-T-P-S), according to the protein MEF2A.

Physical form

Solution in phosphate-buffered saline containing 0.02% sodium azide and 50% glycerol

Target description

The process of differentiation from mesodermal precursor cells to myoblasts has led to the discovery of a variety of tissue-specific factors that regulate muscle gene expression. The myogenic basic helix-loop-helix proteins, including myoD (MIM 159970), myogenin (MIM 159980), MYF5 (MIM 159990), and MRF4 (MIM 159991) are one class of identified factors. A second family of DNA binding regulatory proteins is the myocyte-specific enhancer factor-2 (MEF2) family. Each of these proteins binds to the MEF2 target DNA sequence present in the regulatory regions of many, if not all, muscle-specific genes. The MEF2 genes are members of the MADS gene family (named for the yeast mating type-specific transcription factor MCM1, the plant homeotic genes 'agamous' and 'deficiens' and the human serum response factor SRF (MIM 600589)), a family that also includes several homeotic genes and other transcription factors, all of which share a conserved DNA-binding domain.